Gilead Expands ADC Portfolio with $3.15B Acquisition of Tubulis
Gilead has agreed to acquire German startup Tubulis for an upfront payment of $3.15 billion. This marks the company’s third acquisition of 2026.
Deal details
The payment is being made upfront. The target is Tubulis, a German biotech firm.
Tubulis is known for a next-generation antibody-drug conjugate platform. The platform aims to advance targeted oncology treatments.
Strategic context
Gilead, based in California, is strengthening its presence in targeted therapies. The move expands its research capabilities in antibody-drug conjugates.
Gilead expands its ADC portfolio by committing significant capital to Tubulis. The $3.15 billion upfront payment highlights the company’s strategic priority.
What this means
The acquisition adds a next-generation ADC platform to Gilead’s assets. It also represents a major investment in biotech innovation.
Industry watchers will monitor integration and development activities closely. The outcome could influence future ADC research and partnerships.
About the company
Tubulis is a German startup focused on antibody-drug conjugates. The company developed technologies intended to improve targeted drug delivery.
This report is published by Filmogaz.com, based on available deal information.
